Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. FDA label
Also known as Avastin
Bevacizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| I | OTHER | This is a Phase I safety study. There is only one arm. |
| Name | Type | Description |
|---|---|---|
| bevacizumab, everolimus, panitumumab | DRUG | Cohort # subjects Bevacizumab Everolimus Panitumumab * 3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks * 2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks * 1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks 1. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks 2. 3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD\* RPTD\* RPTD\* 3b 10 RPTD\*\* RPTD\*\* RPTD\*\* * Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. \*\*Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15. |
Inclusion Criteria: * Patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Disease must be measurable or evaluable by RECIST criteria. * Patients must not have had ra...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Bevacizumab is being studied for the treatment of solid tumors. It is an investigational monoclonal antibody in Phase 1 clinical development. It has not been established as a treatment for any condition outside of clinical research.
Bevacizumab targets VEGFA, vascular endothelial growth factor A. It is classified as an inhibitor of this target. By binding VEGFA, the monoclonal antibody is designed to interfere with VEGF-mediated signaling in solid tumors.
Amgen Inc. (ticker AMGN) is the developer of bevacizumab. The company is responsible for the clinical development program evaluating the monoclonal antibody in solid tumors.
Bevacizumab is in Phase 1 clinical development. The program includes one completed Phase 1 trial with no active trials currently listed. It is investigational and has not been approved by the FDA for any indication.
Bevacizumab has been evaluated in the Phase 1 BEP Study (NCT00586443), titled "BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)." The trial enrolled 56 participants with solid tumors in the United States and is completed. It was an uncontrolled study without randomization or blinding.
Bevacizumab is also known by the names everolimus, panitumumab, and Avastin. These alternative names refer to the same drug asset in this development program.